ArticlePLoS neglected tropical diseases2020
A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus.
Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Immunopharmacological and structural design of a polyprotein based multi epitope vaccine against Powassan virus.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Protective human antibodies against Powassan virus.Journal of virology · 2026Article
- Pathogenicity and virulence of Powassan virus.Virulence · 2025Review
- The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine.NPJ vaccines · 2025Article
- Innate Immune Response to Powassan Virus Infection: Progress Toward Infection Control.Vaccines · 2025Review
- The Immunogenicity of an Artificial Tick-Borne Encephalitis Virus Polyepitope Immunogen May Depend on Spacers Flanking Epitope.Bulletin of experimental biology and medicine · 2025Article
- Neurological Complications Associated With the Powassan Virus and Treatment Interventions.Cureus · 2024Review
- Immunoinformatics and computational approaches driven designing a novel vaccine candidate against Powassan virus.Scientific reports · 2024Article
- A Fatal Case of Powassan Virus Encephalitis.Journal of Brown hospital medicine · 2024Article
- Neuroinvasion of emerging and re-emerging arboviruses: A scoping review.SAGE open medicine · 2024Article
- Early transcriptomic changes at the skin interface during Powassan virus transmission byFrontiers in immunology · 2024Article
- T Cells in Tick-Borne Flavivirus Encephalitis: A Review of Current Paradigms in Protection and Disease Pathology.Viruses · 2023Review
- Article
- Generation of Multiple Arbovirus-like Particles Using a Rapid Recombinant Vaccinia Virus Expression Platform.Pathogens (Basel, Switzerland) · 2022Article
- Fatal Powassan virus encephalitis in patients with chronic lymphocytic leukemia.Blood cancer journal · 2022Article
- A Powassan virus domain III nanoparticle immunogen elicits neutralizing and protective antibodies in mice.PLoS pathogens · 2022Article
- Balanced T and B cell responses are required for immune protection against Powassan virus in virus-like particle vaccination.Cell reports · 2022Article
- A Virus-Like Particle-Based Vaccine Candidate against the Tick-Borne Powassan Virus Induces Neutralizing Antibodies in a Mouse Model.Pathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
Powassan virus (POWV) infection is a tick-borne emerging infectious disease in the United States and North America. Like Zika virus, POWV is a member of the family Flaviviridae. POWV causes severe neurological sequalae, meningitis, encephalitis, and can cause death. Although the risk of human POWV infection is low, its incidence in the U.S. in the past 16 years has increased over 300%, urging immediate attention. Despite the disease severity and its growing potential for threatening larger populations, currently there are no licensed vaccines which provide protection against POWV. We developed a novel synthetic DNA vaccine termed POWV-SEV by focusing on the conserved portions of POWV pre-membrane and envelope (prMEnv) genes. A single immunization of POWV-SEV elicited broad T and B cell immunity in mice with minimal cross-reactivity against other flaviviruses. Antibody epitope mapping demonstrated a similarity between POWV-SEV-induced immune responses and those elicited naturally in POWV-infected patients. Finally, POWV-SEV induced immunity provided protection against POWV disease in lethal challenge experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.